Although there is a long tradition of treating asthma with anti-CysLTs [69] and asthma may not be a classical comorbidity of atherosclerosis, some interesting indications were obtained from a randomized controlled trial of placebo versus the CysLT1R antagonist montelukast, which reported significantly lower levels of C-reactive protein in treated patients with severe asthma [55]. Here, CYSLTR1 is linked to atherosclerosis.